RSS-Feed abonnieren
DOI: 10.1055/s-2001-11154
Pilot study of interferon-α high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C
Publikationsverlauf
14.9.2000
26.10.2000
Publikationsdatum:
31. Dezember 2001 (online)

Summary
Ribavirin plus interferon-α (IFNα) combination has led to a marked advance in the treatment of IFNα-naive or relapser patients with chronic hepatitis C but was shown to be only marginally effective in IFNα-nonresponders. We therefore conducted a pilot study to see whether an intensified treatment protocol might be more effective in inducing a virological response in patients who had not responded virologically to previous IFNα monotherapy. 14 nonresponder patients with histologically proven chronic hepatitis C were included in the study. Patients received 9 MU IFNα-2a daily for one week followed by 9 MU IFNα every second day for further 5 weeks. With the beginning of the seventh week, patients were treated with 6 MU IFNα thrice in week (tiw) for a period of 6 weeks (until week 12). IFNα was continued up to 48 weeks at a dose of 3 MU IFNα tiw. Ribavirin (1000-1200 mg/day) and amantadine sulphate (200 mg/day) was given orally for 48 weeks. One patient discontinued therapy after first IFNα injection and one other patient after 12 weeks of therapy because of side effects. The remaining 12 patients completed treatment according to the protocol. An initial virological response at week 24 was achieved in 2 of the 14 patients (14 %) and both patients remained HCV RNA negative at the end of treatment. However, both patients relapsed 4 weeks after completion of therapy, and therefore none of the patients achieved a virological sustained response. Viral dynamics studies showed a marked decline in hepatitis C viremia during the first 6 weeks of high-dose IFNα. After IFNα dose reduction, however, viremia stabilized or increased in most patients. These data indicate, that even triple therapy with high-dose IFNα plus ribavirin and amantadine fails to improve significantly the response rates in IFNα-nonresponders.
Interferon-α-Hochdosis-Induktionstherapie in Kombination mit Ribavirin plus Amantadin bei Nonresponderpatienten mit chronischer Hepatitis C: Ergebnisse einer Pilotstudie
Die Kombinatonstherapie aus Interferon-α (IFNα) plus Ribavirin hat zu einer deutlichen Verbesserung der Ansprechraten bei unvorbehandelten bzw. Relapsepatienten mit chronischer Hepatitis C geführt, war jedoch nur marginal wirksam bei IFNα-Nonrespondern. In der vorliegenden Pilotstudie sind wir der Frage nachgegangen, ob durch eine intensivierte antivirale Therapie eine Verbesserung der Responseraten bei virologischen Nonrespondern erzielt werden kann. 14 Nonresponderpatienten mit histologisch gesicherter chronischer Hepatitis C wurden in die Studie eingeschlossen. Die Patienten erhielten 9 Mio. Einh. IFNα-2a täglich für 7 Tage gefolgt von 9 Mio. Einh. IFNα alle 2 Tage für 5 Wochen. Anschließend (Woche 7-12) wurden die Patienten mit 3 × 6 Mio. Einh. IFNα/Woche gefolgt von 3 × 3 Mio. Einh./Woche (Woche 13-48) behandelt. Zusätzlich erhielten alle Patienten Ribavirin (1000-1200 mg/Tag) und Amantadinsulfat (200 mg/Tag) für 48 Wochen. Ein Patient beendete die Therapie nach der ersten IFNα-Injektion und ein weiterer nach der 12. Therapiewoche aufgrund von Nebenwirkungen. Die übrigen 12 Patienten führten die Therapie protokollgemäß durch. Eine initiale virologische Response zur Woche 24 wurde nur bei 2 der 14 Patienten (14 %) erreicht, und beide Patienten erlitten 4 Wochen nach Therapieende einen Relapse. Untersuchungen zur Dynamik der Hepatitis-C-Virämie zeigten eine signifikante Reduktion der Virusreplikation während der ersten 6 Induktionstherapiewochen. Nach IFNα-Dosisreduktion zeigten allerdings die meisten Patienten eine Stabilisierung bzw. einen Anstieg der Virämie. Unsere Daten zeigen, dass eine antivirale Tripeltherapie mit Hochdosis-IFNα plus Ribavirin und Amantadin nicht in der Lage ist, die dauerhaften Responseraten bei IFNα- Nonrespondern mit ungünstigen Responsefaktoren zu verbessern.
Key words
Hepatitis C Virus Kinetics - High-Dose Interferon-α - Triple Therapy - Amantadine - Ribavirin
Schlüsselwörter
Hepatitis-C-Virus-Kinetik - Hochdosis-Interferon-α - Tripeltherapie - Amantadin - Ribavirin
References
- 1
Alberti A, Chemello L, Noventa F, Cavaletto L, DE
Salvo G.
Therapy of hepatitis C: Re-treatment with alpha
interferon.
Hepatology.
1997;
26 (Suppl.
1)
137-142S
MissingFormLabel
- 2
Kakumu S, Yoshioka K, Wakita T. et al .
A pilot study of ribavirin and interferon beta for the retreatment of chronic
hepatitis
C.
Gastroenterology.
1993;
105
507-512
MissingFormLabel
- 3
Brillanti S, Migliolo M, Barbara L.
Combination antiviral therapy with ribavirin and interferon alfa in interferon
alfa relapsers and nonresponders: Italian experience.
J
Hepatol.
1995;
23 (Suppl.
2)
13-16
MissingFormLabel
- 4
Schvarcz R, Yun Z B, Sonnerborg A, Weiland O.
Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C
in patients with a previous non-response or non-sustained response to interferon
alone.
J
Med
Virol.
1995;
46
43-47
MissingFormLabel
- 5
Schalm S W, Brouwer J T, Chemello L. et al .
Interferon-ribavirin combination therapy for chronic hepatitis C.
Dig
Dis Sci
(Suppl.):.
1996;
41
131-134
MissingFormLabel
- 6
Teuber G, Berg T, Hoffmann R M. et al .
Retreatment wit interferon-alpha and ribavirin in primary interferon-alpha
non-responders with chronic hepatitis
C.
Digestion.
2000;
61
90-97
MissingFormLabel
- 7
Bellobuono A, Mondazzi L, Tempini S. et al .
Ribavirin and interferon-alpha combination therapy vs. interferon-alpha alone in
the treatment of chronic hepatitis C: A randomized clinical trial.
J Viral
Hepat.
1997;
4
185-191
MissingFormLabel
- 8
Wedemeyer H, Jäckel E, Wedemeyer J. et al .
Is combination therapy of chronic hepatitis C with interferon alpha and ribavirin
in primary interferon nonresponders indicated? An analysis of personal experiences
and review of
the
literature.
Z Gastroenterol.
1998;
36
819-827
MissingFormLabel
- 9
Salmeron J, Ruiz-Extremera A, Torres C. et al .
Interferon versus ribavirin plus interferon in chronic hepatitis C previously
resistant to interferon: A randomized
trial.
Liver.
1999;
19
275-280
MissingFormLabel
- 10
Andreone P, Gramenzi A, Cursaro C. et al .
Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous
interferon-alpha course: Results of a randomized multicenter
trial.
J Hepatol.
1999;
30
788-793
MissingFormLabel
- 11
Pol S, Couzigou P, Bourliere M. et al .
A randomized trial of ribavirin and interferon-alpha in patients with chronic
hepatitis C who were nonresponders to a previous treatment.
Multicenter Study Group under
the coordination of Necker Hospital, Paris, France. J
Hepatol.
1999;
31
1-7
MissingFormLabel
- 12
Tromm A, Greving I, Griga T, Mankel K, Huppe D.
Interferon-alpha-2b + ribavirin for the treatment of chronic hepatitis C in
non-responders to interferon-alpha-monotherapy.
Z
Gastroenterol.
2000;
38
159-164
MissingFormLabel
- 13
Smith J P.
Treatment of chronic hepatitis C with amantadine.
Dig Dis
Sci.
1997;
42
1681-1687
MissingFormLabel
- 14
Younossi Z M, Perillo R P.
The roles of amantadine, rimatadine, ursodeoxycholic acid, and NSAIDs, alone or
in combination with alpha interferons, in the treatment of chronic hepatitis
C.
Sem Liver
Dis.
1999;
19 (Suppl.
1)
95-102
MissingFormLabel
- 15
Caronia S, Crossey M, Murray-Lyon I. et al .
A pilot study of interferon plus amantadine versus interferon alone in the
treatment of chronic hepatitis C.
J Hepatol.
1999;
30
(Suppl. 1)
138
MissingFormLabel
- 16
Brillanti S, Foli M, Di
Tomaso M. et al .
Pilot study of triple antiviral therapy for chronic hepatitis C in interferon
alpha non-responders.
Ital J Gastroenterol
Hepatol.
1999;
31
130-134
MissingFormLabel
- 17
Dolin R, Reichmann R C, Madore H P. et al .
A controlled trial of amantadine and rimantadine in the prophylaxis of influenza
A infection.
N Engl J
Med.
1982;
307
580-584
MissingFormLabel
- 18
Hay A J, Wolstenholme A J, Skehel J J, Smith M H.
The molecular basis of the specific anti-influenza action of
amantadine.
EMBO
J.
1985;
4
3021-3024
MissingFormLabel
- 19
Wang C, Takeuchi K, Pinto L H, Lamb R A.
Ion channel activity of influenza A virus M2 protein: Characterization of the
amantadine block.
J
Virol.
1993;
76
5585-5594
MissingFormLabel
- 20
Martin J, Navas S, Fernández M. et al .
In vitro effect of amantadine and interferon-2a on hepatitis C virus markers in
cultured peripheral blood mononuclear cells from hepatitis C virus infected
patients.
Antiviral
Res.
1999;
42
59-70
MissingFormLabel
- 21
Schiffmann M L.
Use of high-dose interferon in the treatment of chronic hepatitis
C.
Semin Liver
Dis.
1999;
19
25-33
MissingFormLabel
- 22
Neumann A U, Lam N P, Dahari H. et al .
Hepatitis C viral dynamics and the antiviral efficacy of interferon-α
therapy.
Science.
1998;
282
103-107
MissingFormLabel
- 23
Lam N, Neumann A, Gretch D. et al .
Dose-dependent acute clearance of hepatitis genotype 1 virus with interferon
alfa.
Hepatology.
1997;
26
226-231
MissingFormLabel
- 24
Desmet V, Gerber M, Hoofnagle J H, Manns M, Scheuer P J.
Classification of chronic hepatitis: Diagnosis, grading and
staging.
Hepatology.
1994;
19
1513-1520
MissingFormLabel
- 25
Hytiroglou P, Tung S N, Gerber A M.
Histological classification and quantitation of the severity of chronic
hepatitis: Keep it simple.
Semin Liver
Dis.
1995;
15
414-421
MissingFormLabel
- 26
Poynard T, Marcellin P, Lee S S. et al .
Randomized trial of interferon (2b plus ribavirin for 48 weeks or 24 weeks versus
interferon (2b plus placebo for 48 weeks for treatment of chronic infection
with hepatitis C
virus.
Lancet.
1998;
352
1426-1432
MissingFormLabel
- 27
McHutchison J G, Gordon S C, Schiff E R. et al .
Interferon alfa-2b alone or in combination with ribavirin as initial treatment
for chronic hepatitis C.
N Engl J
Med.
1998;
339
1485-1492
MissingFormLabel
- 28
Brillanti S, Levantesi F, Foli M, Di
Tomaso M, Bolondi L.
Amantadine and RebetronTM exert a synergistic antiviral effect on HCV
replication in interferon-α non-responders with chronic hepatitis
C.
Gastroenterology.
1999;
116 (Suppl.
1)
212 [Abstract]
MissingFormLabel
- 29
Brillanti S, Levantesi F, Masi L, Foli M, Bolondi L.
Triple antiviral therapy as a new option for patients with interferon
nonresponsive chronic hepatitis
C.
Hepatology.
2000;
32
630-634
MissingFormLabel
- 30
Khalili M, Denham C, Perillo R.
Interferon and ribavirin versus interferon and amantadine in interferon
nonresponders with chronic hepatitis C.
Am J
Gastroenterol.
2000;
95
1284-1289
MissingFormLabel
- 31
Hubert I F, Lunel F, Cadranel J -F, Oberti F, Calès P.
Treatment of chronic hepatitis C with amantadine.
Am J
Gastroenterol.
2000;
95
2316-2317
MissingFormLabel
- 32
Zeuzem S, Teuber G, Naumann U. et al .
Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and
without amantadine as initial treatment for chronic hepatitis
C.
Hepatology.
2000;
32
835-841
MissingFormLabel
- 33
Schiffmann M L, Hofmann C M, Thompson E B. et al .
Relationship between biochemical, virological, and histological response during
interferon treatment of chronic hepatitis
C.
Hepatology.
1997;
26
780-785
MissingFormLabel
- 34
Schiffman M L, Hofmann C M, Contos M J. et al .
A randomized, controlled trial of maintenance interferon therapy for patients
with chronic hepatitis C and persistent
viremia.
Gastroenterology.
1999;
117
1164-1172
MissingFormLabel
- 35
Sobesky R, Mathurin P, Charlotte F. et al .
Modelling the impact of interferon alfa treatment on liver fibrosis progression
in chronic hepatitis C: A dynamic
view.
Gastroenterology.
1999;
116
378-386
MissingFormLabel
- 36
Ikeda K, Saitoh S, Arase Y. et al .
Effect of interferon therapy on hepatocellular carcinogenesis in patients with
chronic hepatitis C: A long-term observation study of 1,643 patients using statistical
bias
correction with proportional hazard
analysis.
Hepatology.
1999;
29
1124-1130
MissingFormLabel
- 37
Bekkering F C, Brouwer J T, Leroux-Roels G. et al .
Ultrarapid hepatitis C virus clearance by daily high-dose interferon in
nonresponders to standard therapy.
J
Hepatol.
1998;
28
960-964
MissingFormLabel
- 38
Berg T, Kaul T, Naumann U, Wiedenmann B, Hopf U.
Influence of ribavirin on the dynamics of hepatitis C viremia in
interferon-alpha-treated patients with response or nonresponse.
Z
Gastroenterol.
2000;
38
1-6
MissingFormLabel
Address for correspondence
Dr. med. Thomas Berg
Medizinische Klinik m. S. Hepatologie und Gastroenterologie
Universitätsklinikum Charité, Campus Virchow-Klinikum
Humboldt-Universität
Augustenburger Platz 1
13353 Berlin
eMail: thomas.berg@charite.de